Humacyte To Announce 2026 First Quarter Financial Results and Provide Business Update on May 13, 2026

Rhea-AI Summary

Humacyte (Nasdaq: HUMA) will release its 2026 first quarter financial results for the period ended March 31, 2026 on May 13, 2026 and will host a webcast and conference call at 8:00 a.m. ET for a corporate and financial update.

The company is a commercial-stage developer of acellular, bioengineered human tissues; its ATEV received FDA approval in December 2024 for vascular trauma and continues in late-stage trials for AV access and PAD. Webcast and dial-in details are provided for investors.

News Market Reaction – HUMA

-1.85%

4 alerts

-1.85% Session close to close

$226.46M Market Cap

0.4x Rel. Volume

In the May 8 session, HUMA declined 1.85%, reflecting a mild negative market reaction. Our momentum scanner triggered 4 alerts that day, indicating moderate trading interest and price volatility.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement sets the timeline for Humacyte’s Q1 2026 financial results on May 13, 2026 and rei...

Analysis

This announcement sets the timeline for Humacyte’s Q1 2026 financial results on May 13, 2026 and reiterates its transition to a commercial-stage model following Symvess’ FDA approval in December 2024. Investors may focus on how the update addresses commercialization progress, late-stage ATEV trials, and capital needs, especially given prior financings and debt facilities highlighted in recent regulatory filings.

Key Figures

Q1 2026 results date: May 13, 2026 Earnings call time: 8:00 a.m. Eastern Time Symvess FDA approval date: December 2024

3 metrics

Q1 2026 results date May 13, 2026 Scheduled release of quarter ended March 31, 2026

Earnings call time 8:00 a.m. Eastern Time Webcast and conference call on May 13, 2026

Symvess FDA approval date December 2024 BLA approval for vascular trauma indication

Previous Earnings date Reports

1 past event · Latest: Mar 23 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 23	Earnings date announcement	Neutral	+8.6%	Announcement of date and time for 2025 year-end results and call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

The last earnings-date announcement was followed by a positive move of 8.61%, suggesting past pre-earnings communications have coincided with upside.

Recent Company History

Recent news has focused on commercialization and pipeline progress, including FDA approval of Symvess for extremity vascular trauma and late‑stage ATEV trials. The prior earnings‑date notice on Mar 23, 2026 preceded an 8.61% gain, while the actual 2025 results on Mar 27, 2026 saw a -13.21% reaction. Against this backdrop, today’s scheduling of the Q1 2026 release on May 13, 2026 fits a pattern of earnings‑linked catalysts drawing investor attention.

Key Terms

biologics license application, acellular tissue engineered vessel, regenerative medicine advanced therapy (rmat) designation, fast track designation, +4 more

8 terms

biologics license application regulatory

"Humacyte’s Biologics License Application for Symvess, the acellular tissue"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

acellular tissue engineered vessel medical

"Symvess, the acellular tissue engineered vessel (ATEV), in the vascular"

Acellular tissue engineered vessels are lab-made replacement blood vessels created from biological materials but manufactured without living cells, so they act like a ready-made tube that the body can grow into and line with its own cells. For investors, they matter because they target a steady medical need (for example, replacing or bypassing damaged vessels) and carry commercial upside if proven safe and long-lasting, while also involving manufacturing, clinical trial and regulatory risks.

regenerative medicine advanced therapy (rmat) designation regulatory

"was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation"

A Regenerative Medicine Advanced Therapy (RMAT) designation is a U.S. regulatory status given to certain cell, gene, or tissue-based treatments that show promise for serious conditions and early clinical evidence of benefit. It signals that regulators will provide extra guidance and expedited review steps—like giving a promising project a “fast pass” through some development checkpoints—which can shorten time to market and reduce regulatory risk, making the program more valuable and noteworthy to investors.

fast track designation regulatory

"and has also received FDA Fast Track designation."

Fast track designation is a status the U.S. Food and Drug Administration grants to drugs intended to treat serious conditions and address an unmet medical need. It gives the developer more frequent communication with the FDA and can allow parts of the application to be reviewed on a rolling basis, and it may pave the way to priority review or accelerated approval. It can shorten development timelines, though it does not guarantee approval.

arteriovenous (av) access medical

"late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis"

A surgical connection created between an artery and a vein so blood can be removed and returned efficiently during kidney dialysis; think of it as installing a durable high-flow hose connection that lets medical teams hook up and run treatment repeatedly without damaging the vessels. Investors care because the quality, durability and complication rate of AV access affect demand for related procedures, medical devices and services, influence healthcare costs and reimbursement, and can drive revenue and liability risks for device makers and dialysis providers.

peripheral artery disease (pad) medical

"arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD)."

Peripheral artery disease (PAD) is a condition in which fatty deposits narrow or block the arteries that carry blood to the legs and feet, causing pain, slow wound healing and higher risk of infection or tissue loss. Investors care because PAD drives demand for diagnostic tests, drugs, implants and surgical procedures, influences healthcare spending and insurance payments, and creates business risk or opportunity tied to clinical trial outcomes, regulatory approval and reimbursement decisions.

hemodialysis medical

"AV access for hemodialysis and peripheral artery disease (PAD)."

Hemodialysis is a medical treatment that cleans a person’s blood when their kidneys can no longer do the job, by routing blood through a machine that filters out waste, excess fluid and adjusts salt levels—think of it as an external, mechanical kidney. It matters to investors because it drives demand for specialized machines, replacement filters, clinics, trained staff and related drugs, and is sensitive to reimbursement rules, treatment volumes and advances that can change costs or market share.

vascular trauma medical

"for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved"

Vascular trauma is injury to arteries or veins caused by accidents, surgical procedures, or violent events that leads to bleeding, clotting, or reduced blood flow to organs and tissues. For investors, it matters because treating these injuries often requires specialized devices, emergency supplies, or surgical services, creating demand drivers, regulatory scrutiny, and reimbursement considerations for companies that make implants, hemostatic products, and vascular repair technologies.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale, today announced that the Company will release its financial results for the quarter ended March 31, 2026 on Wednesday, May 13, 2026. Management will host a webcast and conference call at 8:00 a.m. Eastern Time to provide a corporate and financial update.

Title	Humacyte 2025 First Quarter Financial Results and Corporate Update
Date	May 13, 2026
Time	8:00 a.m. Eastern Time
Conference Details	1-877-704-4453 (U.S. Investors) 1-201-389-0920 (International Investors) 13760221 (Conference ID)
Call meTM	Click Here
Webcast	Click Here

About Humacyte

Humacyte, Inc. (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s Biologics License Application for Symvess, the acellular tissue engineered vessel (ATEV), in the vascular trauma indication was approved by the FDA in December 2024. ATEVs are also currently in late-stage clinical trials targeting other vascular applications, including arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD). The Company is preparing for human clinical study in coronary artery bypass graft surgery, and preclinical development is also underway in the treatment of type 1 diabetes, pediatric heart disease, and multiple novel cell and tissue applications. Humacyte’s 6mm ATEV for AV access in hemodialysis was the first product candidate to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) designation and has also received FDA Fast Track designation. Humacyte’s 6mm ATEV for urgent arterial repair following extremity vascular trauma and for advanced PAD also have received RMAT designations. The ATEV received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.

For uses other than the FDA approval in the extremity vascular trauma indication, the ATEV is an investigational product and has not been approved for sale by the FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties, and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, our plans and ability to commercialize Symvess and, if approved by regulatory authorities, our product candidates, successfully and on our anticipated timelines; the degree of market acceptance of and the availability of third-party coverage and reimbursement for Symvess and, if approved by regulatory authorities, our product candidates; our ability to manufacture Symvess and, if approved by regulatory authorities, our product candidates in sufficient quantities to satisfy our clinical trial and commercial needs; the anticipated benefits of our ATEVs relative to existing alternatives; our plans and ability to execute product development, process development and preclinical development efforts successfully and on our anticipated timelines; our ability to design, initiate and successfully complete clinical trials and other studies for our product candidates and our plans and expectations regarding our ongoing or planned clinical trials; the anticipated characteristics and performance of our ATEVs; the implementation of our business model and strategic plans for our business; our ability to execute and achieve the expected benefits of our cost-saving measures and whether our efforts will result in further actions or additional asset impairment charges that adversely affect our business; and the timing or likelihood of regulatory filings, acceptances and approvals. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Humacyte may be adversely affected by other economic, business, competitive and/or reputational factors, and other risks and uncertainties, including those described under the header “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2025 filed by Humacyte with the SEC, and in future SEC filings. Most of these factors are outside of Humacyte’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. Except as required by law, we have no current intention of updating any of the forward-looking statements in this press release. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Humacyte Investor Contact:
Joyce Allaire
LifeSci Advisors LLC
+1-617-435-6602
jallaire@lifesciadvisors.com
investors@humacyte.com

Humacyte Media Contact:
Rich Luchette
Precision Strategies
+1-202-845-3924
rich@precisionstrategies.com
media@humacyte.com

FAQ

When will Humacyte (HUMA) report Q1 2026 results and how can I join the May 13, 2026 call?

Humacyte will report Q1 2026 results on May 13, 2026 at 8:00 a.m. ET. According to the company, investors can join via the provided webcast link or by dialing 1-877-704-4453 (U.S.) with conference ID 13760221.

What is Humacyte's (HUMA) regulatory status for its ATEV product as of May 2026?

The ATEV received FDA approval in December 2024 for the vascular trauma indication. According to the company, other ATEV uses remain investigational and are in late-stage trials for AV access and PAD.

Will Humacyte (HUMA) discuss clinical programs like AV access and PAD during the May 13, 2026 update?

The company will provide a corporate and financial update on the call at 8:00 a.m. ET. According to the company, clinical programs including AV access and PAD are current late-stage priorities likely to be addressed in the webcast.

How did Humacyte (HUMA) describe its business and product focus in the May 8, 2026 notice?

Humacyte describes itself as a commercial-stage developer of acellular, bioengineered human tissues at scale. According to the company, it targets vascular trauma, AV access, PAD, and additional preclinical applications.

Where can investors find Humacyte (HUMA) investor materials and the May 13, 2026 webcast recording?

Investors can access materials and the live webcast via the company's investor relations site and webcast link. According to the company, archived recordings and call details will be posted on its website after the event.